TY - JOUR T1 - Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy JF - The Journal of Rheumatology JO - J Rheumatol SP - 117 LP - 118 DO - 10.3899/jrheum.180566 VL - 46 IS - 1 AU - JILL RUWAARD AU - EVA R. VAN DER VLUGT AU - GERTJAN WOLBINK Y1 - 2019/01/01 UR - http://www.jrheum.org/content/46/1/117.abstract N2 - Biological treatment is an effective treatment for various chronic inflammatory diseases1,2. Nevertheless, reports of paradoxical immune-mediated inflammation induced by biologicals are increasing3. A paradoxical adverse event is defined as the development of inflammatory manifestations in patients after the initiation of biologicals, mostly tumor necrosis factor inhibitors (TNFi), normally used to treat such disorders3. Palmoplantar pustulosis (PPP) and psoriasis vulgaris (PV) are the most described paradoxical cutaneous adverse events4. Although studies show that PPP and PV are different entities, they are analyzed as 1 group of paradoxical cutaneous diseases5. Consequently, individual prevalence of paradoxical PPP and PV, and associated differences regarding the clinical consequence, are still unknown.To study these differences, we retrospectively collected data from 2000 to 2015 of the Reade Rheumatology Registry, an observational cohort of patients with biological-treated ankylosing spondylitis (AS) and rheumatoid arthritis (RA). The 5 different TNFi, abatacept (ABA), tocilizumab (TCZ), and rituximab were included. Further, each patient received a multiple-choice questionnaire, from June 2016 … Address correspondence to Dr. J. Ruwaard, Amsterdam Rheumatology and Immunology Center, location Reade, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, the Netherlands. E-mail: j.ruwaard{at}reade.nl ER -